IN8bio, Inc..
INAB.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. The company's lead programs include DeltEx therapies, which are designed to selectively kill cancer cells while sparing ...Show More
Better Health for All
10
The company's core business, developing gamma-delta T cell therapies for cancer,
1
demonstrates a revolutionary health impact. Clinical trials for INB-100 in AML show 100% progression-free survival and overall survival at one year,
2
with some patients relapse-free for over three and a half years,
3
significantly exceeding historical controls.
4
For INB-200 in glioblastoma, one patient remains progression-free for four years,
5
and the median progression-free survival of 16.1 months
6
significantly exceeds the standard-of-care's 6.9 months.
7
The company has no revenue from products with established negative health outcomes. Both INB-100 and INB-200 have demonstrated favorable safety profiles with no dose-limiting toxicities,
8
cytokine release syndrome,
9
neurotoxicity,
10
or treatment-related deaths.
11
However, one patient in the INB-100 trial died of idiopathic pulmonary fibrosis, a known transplant toxicity.
12
The company laid off approximately 49% of its workforce,
13
reducing full-time employees from 37 to 19,
14
and cut executive pay by 11%.
15
The company is a clinical-stage biopharmaceutical company developing innovative therapies,
16
but a specific percentage of R&D budget allocated to health improvement is not provided. The company's clinical trials include high-risk and relapsed AML patients,
17
as well as older patients (median age 68),
18
and haploidentical donors increase access for under-represented groups,
19
but a specific percentage of vulnerable populations reached is not available. The company conducts investigator-sponsored dose-escalation trials,
20
has received FDA guidance,
21
and discloses primary and secondary endpoints, including safety and tolerability, relapse rate, and overall survival.
22
It also reported one patient death from a known transplant toxicity.
23
Fair Money & Economic Opportunity
0
No evidence available to assess IN8bio, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific, concrete data points were found in the provided articles for any of the KPIs related to Fair Pay & Worker Respect. Information regarding living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, voluntary employee turnover rate, labor violation incidents, insecure contract share, or the percentage of the workforce with employer-funded health insurance was not explicitly stated. While articles mentioned executive compensation details, a workforce reduction (involuntary turnover), and the eligibility of executive officers for health insurance on the same basis as other employees, these facts did not provide the quantitative metrics required by the rubric for scoring.
1
Fair Trade & Ethical Sourcing
0
No evidence available to assess IN8bio, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No specific, quantitative evidence was found across the provided articles to assess INAB.US against any of the defined KPIs for the 'Honest & Fair Business' ethical value. The articles primarily focus on clinical trial results or provide general overviews of corporate governance documents without specific details on compliance, regulatory issues, or performance against benchmarks. The absence of mention of fines or other issues is not considered evidence for scoring purposes.
Kind to Animals
0
No specific, concrete data points were found in the provided articles for any of the KPIs related to the 'Kind to Animals' value. The articles are primarily financial reports and press releases detailing funding, clinical trial progress, and corporate operations. While the company, a clinical-stage biopharmaceutical firm, mentions expecting to generate 'early animal model data' for initial discussions with the U.S. Food and Drug Administration (FDA) in 2026 and 'pivotal animal model data' and potential IND submission in 2027, this information does not provide details on animal testing policies, volumes, alternative testing usage, humane certifications, or any other animal welfare-related metrics required by the rubric.
1
Statements about future operational activities involving animal models do not constitute evidence for the defined KPIs.
No War, No Weapons
0
Based on the provided documents, there is insufficient evidence to assess IN8bio's alignment with the 'No War, No Weapons' value. The company is a clinical-stage biopharmaceutical company focused on developing cancer therapies, and its activities do not appear to involve arms manufacturing, military contracts, or conflict facilitation. The provided articles focus on the company's research and development activities, financial results, and conflict mineral policies of unrelated companies.
1
,
2
,
3
,
4
,
5
,
6
,
7
,
8
Given the lack of relevant information, a neutral score of 0 is assigned. The company's business model is fundamentally neutral with respect to the 'No War, No Weapons' value, as indicated by the materiality analysis.
Planet-Friendly Business
0
The provided articles, including annual reports and financial summaries, do not contain specific, concrete data points for any of the Planet-Friendly Business KPIs. Statements such as 'Not found', 'Not applicable', or 'Not explicitly stated' for various metrics, or a general 'SDG Transparency Score' without further detail, do not constitute actionable evidence for scoring against the rubric's quantitative thresholds. Therefore, all KPIs for this value are omitted due to a lack of explicit factual evidence.
Respect for Cultures & Communities
0
No evidence available to assess IN8bio, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess IN8bio, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence was found in the provided articles regarding IN8bio, Inc.'s waste diversion rates, product recyclability, packaging sustainability, use of recycled content, single-use plastic reduction efforts, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certifications, waste disposal violations, material efficiency, packaging to product ratio, waste reduction targets, supplier waste requirements, or customer waste education programs.
1